Nebivolol elicits a neuroprotective effect in the cuprizone model of multiple sclerosis in mice: emphasis on M1/M2 polarization and inhibition of NLRP3 inflammasome activation
- PMID: 35948811
- PMCID: PMC9700639
- DOI: 10.1007/s10787-022-01045-4
Nebivolol elicits a neuroprotective effect in the cuprizone model of multiple sclerosis in mice: emphasis on M1/M2 polarization and inhibition of NLRP3 inflammasome activation
Abstract
Background and aim: Multiple sclerosis (MS) is a demyelinating neurodegenerative inflammatory disease affecting mainly young adults. Microgliosis-derived neuroinflammation represents a key hallmark in MS pathology and progression. Nebivolol (Neb) demonstrated antioxidant, anti-inflammatory and neuroprotective properties in several brain pathologies. This study was conducted to investigate the potential neuroprotective effect of Neb in the cuprizone (Cup) model of MS.
Methods: C57Bl/6 mice were fed 0.2% Cup mixed into rodent chow for 5 weeks. Neb (5 and 10 mg/kg/day) was administered by oral gavage during the last 2 weeks.
Results: Neb prevented Cup-induced weight loss and motor deficits as evidenced by increased latency to fall in the rotarod test and enhanced locomotor activity as compared to Cup-intoxicated mice. Neb reversed Cup-induced demyelination as confirmed by Luxol fast blue staining and myelin basic protein western blotting. Administration of Neb modulated microglial activation status by suppressing M1 markers (Iba-1, CD86, iNOS, NO and TNF-α) and increasing M2 markers (Arg-1 and IL-10) as compared to Cup-fed mice. Furthermore, Neb hindered NLRP3/caspase-1/IL-18 inflammatory cascade and alleviated oxidative stress by reducing lipid peroxidation, as well as increasing catalase and superoxide dismutase activities.
Conclusion: These findings suggest the potential neuroprotective effect of Neb in the Cup-induced model of MS in mice, at least partially by virtue of shifting microglia towards M2 phenotype, mitigation of NLRP3 inflammasome activation and alleviation of oxidative stress.
Keywords: Cuprizone; M1/M2 polarization; Multiple sclerosis; NLRP3; Nebivolol.
© 2022. The Author(s).
Conflict of interest statement
The authors have no relevant financial or non-financial interests to disclose.
Figures












Similar articles
-
Progesterone therapy induces an M1 to M2 switch in microglia phenotype and suppresses NLRP3 inflammasome in a cuprizone-induced demyelination mouse model.Int Immunopharmacol. 2017 Oct;51:131-139. doi: 10.1016/j.intimp.2017.08.007. Epub 2017 Aug 19. Int Immunopharmacol. 2017. PMID: 28830026
-
TGN020 application against aquaporin 4 improved multiple sclerosis by inhibiting astrocytes, microglia, and NLRP3 inflammasome in a cuprizone mouse model.J Chem Neuroanat. 2023 Oct;132:102306. doi: 10.1016/j.jchemneu.2023.102306. Epub 2023 Jun 30. J Chem Neuroanat. 2023. Retraction in: J Chem Neuroanat. 2024 Sep;139:102445. doi: 10.1016/j.jchemneu.2024.102445. PMID: 37394105 Retracted.
-
17β-Estradiol Reduces Demyelination in Cuprizone-fed Mice by Promoting M2 Microglia Polarity and Regulating NLRP3 Inflammasome.Neuroscience. 2021 May 21;463:116-127. doi: 10.1016/j.neuroscience.2021.03.025. Epub 2021 Mar 29. Neuroscience. 2021. PMID: 33794337
-
The dual face of microglia (M1/M2) as a potential target in the protective effect of nutraceuticals against neurodegenerative diseases.Front Aging. 2023 Sep 6;4:1231706. doi: 10.3389/fragi.2023.1231706. eCollection 2023. Front Aging. 2023. PMID: 37744008 Free PMC article. Review.
-
Modulation of the Microglial Nogo-A/NgR Signaling Pathway as a Therapeutic Target for Multiple Sclerosis.Cells. 2022 Nov 25;11(23):3768. doi: 10.3390/cells11233768. Cells. 2022. PMID: 36497029 Free PMC article. Review.
Cited by
-
Targeting NLRP3 Inflammasomes: A Trojan Horse Strategy for Intervention in Neurological Disorders.Mol Neurobiol. 2025 Feb;62(2):1840-1881. doi: 10.1007/s12035-024-04359-2. Epub 2024 Jul 23. Mol Neurobiol. 2025. PMID: 39042218 Review.
-
Mechanisms underlying the beneficial effects of physical exercise on multiple sclerosis: focus on immune cells.Front Immunol. 2023 Sep 29;14:1260663. doi: 10.3389/fimmu.2023.1260663. eCollection 2023. Front Immunol. 2023. PMID: 37841264 Free PMC article. Review.
-
The role of NLRP3 inflammasome in multiple sclerosis: pathogenesis and pharmacological application.Front Immunol. 2025 Apr 2;16:1572140. doi: 10.3389/fimmu.2025.1572140. eCollection 2025. Front Immunol. 2025. PMID: 40242770 Free PMC article. Review.
-
Microglial Mayhem NLRP3 Inflammasome's Role in Multiple Sclerosis Pathology.CNS Neurosci Ther. 2024 Dec;30(12):e70135. doi: 10.1111/cns.70135. CNS Neurosci Ther. 2024. PMID: 39690733 Free PMC article. Review.
-
Inflammasomes in neurological disorders - mechanisms and therapeutic potential.Nat Rev Neurol. 2024 Feb;20(2):67-83. doi: 10.1038/s41582-023-00915-x. Epub 2024 Jan 9. Nat Rev Neurol. 2024. PMID: 38195712 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous